Top Markets
#1 DogBull DogBull +105.03%
#2 ADO Protocol ADO Protocol +63.41%
#3 Siacoin Siacoin +46.50%
#4 MarsCoin MarsCoin +37.49%
#5 Useless Coin Useless Coin +36.09%
#6 Ontology Gas Ontology Gas +27.76%
#7 UnifAI Network UnifAI Network +27.18%
#8 Glidr Glidr +19.86%
#9 Falcon Finance Falcon Finance +17.20%
#10 Apertum Apertum +14.82%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Rank in Stocks #15973
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Share Price
$15.42
Market Cap
$320.83M
Change (1 day)
-1.52%
Change (1 year)
40.67%
Country
IT
Trade Newron Pharmaceuticals S.p.A. (NP5)

Category

Healthcare
Revenue for Newron Pharmaceuticals S.p.A. (NP5)
Revenue in Sep 2026 TTM: 0
According to Newron Pharmaceuticals S.p.A. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Newron Pharmaceuticals S.p.A. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH